Mortality rates among United States veterans with sarcoidosis have been rising since 2004, most notably in men, according to ...

Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...

Among those treated for sarcoidosis in the year following diagnosis, 60% used steroids alone, 13% nonsteroidal immunosuppressives alone, and 27% received both. About 43% of patients with sarcoidosis ...

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...

Sarcoidosis is an inflammatory disease that can affect any organ in the body, although it is most commonly found in the lungs and lymph nodes. The condition is characterized by the formation of ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

1 Pathology Department, Shahid Sadoghi University, Yazd, Islamic Republic of Iran 2 Internal Medicine Department, Shahid Sadoghi University, Yazd, Islamic Republic of Iran 3 Shahid Sadoghi Hospital, ...

Nov. 6, 2024 — Exhaled breath contains chemical clues to what's going on inside the body, including diseases like lung cancer. And devising ways to sense these compounds could help doctors ...

The increase in the global burden of interstitial lung disease (ILD) and pulmonary sarcoidosis had the greatest impact on countries with a high sociodemographic index. This recent study highlights ...

Efzofitimod is under clinical development by aTyr Pharma and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

The author has no conflicts of interest to disclose. Sarcoidosis is a disorder that affects multiple systems with unclear causes and is relatively rare. The defining characteristic of this disease is ...